Here are the DEF 14A proxy statements from Halozyme Therapeutics, Inc. (HALO) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow HALO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HALO filings page.
Halozyme Therapeutics, Inc. has issued its 2026 proxy for an online-only annual stockholder meeting on May 5, 2026. Stockholders will vote on electing two Class I directors, an advisory say-on-pay resolution for named executive officers, and ratifying Ernst & Young LLP as auditor for 2026.
The Board highlights a majority-vote standard for uncontested director elections, a fully independent board except for the CEO, and active board committees overseeing audit, compensation, and governance. Executive pay is heavily weighted to performance-based equity, with 2025 incentives tied to revenue and Adjusted EBITDA goals and strong stock performance, including record 2025 revenue of $1,397 million and 52% royalty revenue growth.